Wuhan Hiteck Biological PharmaLtd Past Earnings Performance
Past criteria checks 0/6
Wuhan Hiteck Biological PharmaLtd's earnings have been declining at an average annual rate of -69.7%, while the Biotechs industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 2% per year.
Key information
-69.7%
Earnings growth rate
-68.5%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 2.0% |
| Return on equity | -5.8% |
| Net Margin | -22.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Wuhan Hiteck Biological PharmaLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 596 | -136 | 265 | 133 |
| 31 Dec 23 | 602 | -121 | 238 | 129 |
| 30 Sep 23 | 580 | -59 | 242 | 127 |
| 30 Jun 23 | 588 | -44 | 238 | 115 |
| 31 Mar 23 | 661 | -23 | 235 | 116 |
| 01 Jan 23 | 689 | -14 | 236 | 121 |
| 30 Sep 22 | 769 | 28 | 237 | 116 |
| 30 Jun 22 | 776 | 39 | 253 | 118 |
| 31 Mar 22 | 623 | 21 | 251 | 113 |
| 01 Jan 22 | 615 | 28 | 256 | 103 |
| 30 Sep 21 | 568 | 4 | 245 | 105 |
| 30 Jun 21 | 557 | -14 | 273 | 94 |
| 31 Mar 21 | 617 | -15 | 270 | 95 |
| 31 Dec 20 | 524 | -25 | 255 | 86 |
| 30 Sep 20 | 498 | -16 | 274 | 75 |
| 30 Jun 20 | 494 | 3 | 285 | 71 |
| 31 Mar 20 | 529 | 37 | 339 | 62 |
| 01 Jan 20 | 620 | 63 | 382 | 63 |
| 30 Sep 19 | 649 | 86 | 423 | 53 |
| 30 Jun 19 | 641 | 103 | 415 | 48 |
| 31 Mar 19 | 615 | 100 | 388 | 41 |
| 31 Dec 18 | 591 | 94 | 398 | 30 |
| 30 Sep 18 | 585 | 110 | 391 | 26 |
| 30 Jun 18 | 630 | 119 | 405 | 33 |
| 31 Mar 18 | 712 | 135 | 491 | 24 |
| 31 Dec 17 | 750 | 142 | 519 | 24 |
| 30 Sep 17 | 826 | 168 | 580 | 17 |
| 30 Jun 17 | 827 | 165 | 601 | 0 |
| 31 Mar 17 | 791 | 161 | 686 | 0 |
| 31 Dec 16 | 771 | 157 | 559 | 0 |
| 31 Dec 15 | 679 | 83 | 479 | 0 |
| 31 Dec 14 | 549 | 110 | 401 | 0 |
| 31 Dec 13 | 356 | 78 | 245 | 0 |
Quality Earnings: 300683 is currently unprofitable.
Growing Profit Margin: 300683 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300683 is unprofitable, and losses have increased over the past 5 years at a rate of 69.7% per year.
Accelerating Growth: Unable to compare 300683's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300683 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.9%).
Return on Equity
High ROE: 300683 has a negative Return on Equity (-5.81%), as it is currently unprofitable.